| ORY Stock | | | EUR 1.54 0.02 1.28% |
The current 90-days correlation between Oryzon Genomics SA and ENCE Energa y is -0.28 (i.e., Very good diversification). The correlation of Oryzon Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Oryzon Genomics Correlation With Market
Average diversification
The correlation between Oryzon Genomics SA and DJI is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Oryzon Genomics SA and DJI in the same portfolio, assuming nothing else is changed.
The ability to find closely correlated positions to Oryzon Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oryzon Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oryzon Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oryzon Genomics SA to buy it.
Moving together with Oryzon Stock
Moving against Oryzon Stock
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations | | High negative correlations |
Risk-Adjusted IndicatorsThere is a big difference between Oryzon Stock performing well and Oryzon Genomics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oryzon Genomics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oryzon Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
| | Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Oryzon Genomics Corporate Management
Elected by the shareholders, the Oryzon Genomics' board of directors comprises two types of representatives: Oryzon Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oryzon. The board's role is to monitor Oryzon Genomics' management team and ensure that shareholders' interests are well served. Oryzon Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oryzon Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.